The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease

被引：0
|
作者：
Sollelis, E. [1 ,2 ,3 ]
Quinard, R. Minet [4 ]
Bouguen, G. [5 ]
Goutte, M. [1 ,2 ,3 ]
Goutorbe, F. [1 ,6 ]
Bouvier, D. [4 ]
Pereira, B. [7 ]
Bommelaer, G. [1 ,2 ,3 ]
Buisson, A. [1 ,2 ,3 ]
机构：
[1] Univ Hosp Estaing, Gastroenterol Dept, Clermont Ferrand, France
[2] Univ Auvergne, INSERM, UMR 1071, Clermont Ferrand, France
[3] USC INRA 2018, Microbes Intestine Inflammat & Susceptibil Host, Clermont Ferrand, France
[4] Univ Hosp G Montpied, Biochem Lab, Clermont Ferrand, France
[5] Univ Hosp, Rennes, France
[6] Hosp Bayonne, Gastroenterol Dept, Bayonne, France
[7] Univ Hosp, Biostat Unit, DRCI Clermont Ferrand, Clermont Ferrand, France
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P504
引用
收藏
页码：S360 / S360
页数：1
相关论文
共 50 条
  • [41] ANTI-TNF THERAPY REDUCES IONISING RADIATION EXPOSURE IN PATIENTS WITH CROHN'S DISEASE
    Aggarwal, D.
    Limdi, J. K.
    GUT, 2014, 63 : A79 - A79
  • [42] Anti-TNF therapy use in pregnant patients with Crohn's disease and ulcerative colitis
    Kiely, C.
    Subramaniam, K.
    Pavli, P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 104 - 104
  • [43] Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus
    Gonzalez-Lama, Yago
    Ricart, Elena
    Carpio, Daniel
    Bastida, Guillermo
    Ceballos, Daniel
    Ginard, Daniel
    Marin-Jimenez, Ignacio
    Menchen, Luis
    Munoz, Fernando
    BMJ OPEN GASTROENTEROLOGY, 2024, 11 (01):
  • [44] The variation of faecal calprotectin level within the first months after bowel resection is predictive of endoscopic postoperative recurrence in patients with Crohn's disease
    Boube, M.
    Laharie, D.
    Nancey, S.
    Hebuterne, X.
    Fumery, M.
    Pariente, B.
    Roblin, X.
    Peyrin-Biroulet, L.
    Reymond, M.
    Allimant, C.
    Minet-Quinard, R.
    Pereira, B.
    Bommelaer, G.
    Buisson, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S172 - S173
  • [45] Predictive Factors of Deep Remission Achievement in Patients With Crohn's Disease Treated With Anti-TNF Alfa
    Sebkova, Ladislava
    Rodino, Stefano
    D'Amico, Teresa
    Sacca, Natale
    GASTROENTEROLOGY, 2012, 142 (05) : S228 - S228
  • [46] Anti-TNF Alpha Therapy and Orofacial Crohn's Disease in Pediatrics
    Chapuy, Laurence
    Deslandres, Colette
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S71 - S71
  • [47] Anti-TNF induction and maintenance therapy for refractory Crohn's disease
    Hartnell, F. L.
    Radford-Smith, G.
    Jones, L.
    Sewell, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 62 - 62
  • [48] Impact analysis of expanding anti-TNF therapy for Crohn's disease
    Honeycutt, Amanda
    Breck, Andrew
    Bass, Sarah
    Esposito, Dominick
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (02) : 79 - 88
  • [49] SEVERE CARDIOMYOPATHY SECONDARY TO ANTI-TNF THERAPY FOR CROHN'S DISEASE
    Rezik, Mohamed
    Mattina, Deirdre
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1042 - 1042
  • [50] Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors
    Osamura, Aisaku
    Suzuki, Yasuo
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (01) : 204 - 208
12345